Cannabinoid formulations

Abstract

The present disclosure provides a microparticulate comprising one or more cannabinoids and a pH dependent release polymer. In embodiments, the one or more cannabinoids are present in an amount ranging from 10% w/w to about 50% w/w. In embodiments, the pH dependent release polymer is present in an amount ranging from ranging from about 5% w/w to about 85% w/w.

1 . A microparticulate comprising one or more cannabinoids and a pH dependent release polymer, wherein the one or more cannabinoids are present in an amount ranging from 10% w/w to about 50% w/w, and the pH dependent release polymer is present in an amount ranging from about 5% w/w to about 85% w/w, and wherein the pH dependent release polymer is hydroxypropyl methyl cellulose acetate succinate (HPMCAS). 
     
     
         2 . The microparticulate of  claim 1 , wherein the one or more cannabinoids are:
 cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), tetrahydrocannabivarinic acid (THCVA), or combinations thereof.   
     
     
         3 . The microparticulate of  claim 1 , wherein the one or more cannabinoids comprise CBD, THC, or combinations thereof. 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . The microparticulate of  claim 1 , wherein the HPMCAS is HPMCAS-L, HPMCAS-M, HL HPMCAS-H, or combinations thereof. 
     
     
         7 . The microparticulate of  claim 1 , having a particle size ranging from about 1 μm to about 200 μm. 
     
     
         8 . The microparticulate of  claim 1 , having a particle size ranging from about 5 μm to about 100 μm. 
     
     
         9 . The microparticulate of  claim 1 , wherein the pH dependent release polymer is present as a coating disposed over the one or more cannabinoids. 
     
     
         10 . The microparticulate of  claim 1 , wherein the one or more cannabinoids are dispersed in a matrix comprising the pH dependent release polymer. 
     
     
         11 . (canceled) 
     
     
         12 . A unit dose comprising a plurality of the microparticulates of  claim 1 , further comprising one or more pharmaceutically acceptable excipients. 
     
     
         13 . The unit dose of  claim 12 , wherein the dosage form comprises from 50 mg to about 1000 mg of one or more cannabinoids. 
     
     
         14 - 17 . (canceled) 
     
     
         18 . The microparticulate of  claim 1 , further comprising one or more wetting agents. 
     
     
         19 . The microparticulate of  claim 18 , wherein the one or more wetting agent is a polyoxyethylene-polyoxypropylene block copolymer or sodium carbonate. 
     
     
         20 . The unit dose of  claim 12 , further comprising one or more suspending agents. 
     
     
         21 . The unit dose of  claim 20 , wherein the one or more suspending agents is polysorbate 20, glycerol, or xanthan gum. 
     
     
         22 . The unit dose of  claim 12 , further comprising one or more pH buffers. 
     
     
         23 . The unit dose of  claim 22 , wherein the one or more pH buffers are citric acid, sodium phosphate dibasic, sodium hydroxide, phosphate buffered saline, or combinations thereof. 
     
     
         24 . The unit dose of  claim 12 , further comprising one or more preservatives. 
     
     
         25 . The unit dose of  claim 24 , wherein the one or more preservatives are potassium sorbate, sodium benzoate, or a combination thereof. 
     
     
         26 . The unit dose of  claim 12 , further comprising one or more antioxidants. 
     
     
         27 . The unit dose of  claim 26 , wherein the one or more antioxidants are butylated hydroxyltoluene, butylated hydroxylanisole, alpha-tocopherol (Vitamin E), ascorbyl palmitate, ascorbic acid, sodium ascorbate, ethylenediamino tetraacetic acid, cysteine hydrochloride, citric acid, sodium citrate, sodium bisulfate, sodium metabisulfite, lecithin, propyl gallate, sodium sulfate, monothioglycerol, or mixtures thereof. 
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . The unit dose of  claim 12 , wherein the unit dose is formulated as a mucoadhesive gel; a tablet; a powder; a liquid gel capsule; a solid capsule; an oral solution; an oral suspension; a granulate; an extrudate; or a sprinkle.